Recent News

• 09.11.2025 - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.03.2025 - Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism
• 08.27.2025 - Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy
• 08.06.2025 - Travere Therapeutics Reports Second Quarter 2025 Financial Results
• 07.30.2025 - Travere Therapeutics to Report Second Quarter 2025 Financial Results
• 07.11.2025 - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.11.2025 - Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference
• 06.10.2025 - Travere Therapeutics Launches “Play It Forward” Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
• 06.03.2025 - Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress

Recent Filings

• 09.10.2025 - 8-K Current report
• 09.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.06.2025 - 8-K Current report
• 08.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2025 - EX-99.1 EX-99.1
• 07.29.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.02.2025 - 4 Statement of changes in beneficial ownership of securities